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I n t r o d u c t i o n  
The success of hematopoietic stem cell transplantation (HSCT) in children can be 
related to improved HSCT strategies, better supportive care, and a greater understand- 
ing of the transplant process, immune status, tolerance, and graft versus host disease 
(GVHD).’ GVHD occurs when the donor’s immune system rejects the recipient’s body, 
and has been associated with significant morbidity and mortality.’ The autoreactive T- 
cells mediate damage through direct tissue attack and secretion of cytokines but the 
disease’s basic pathophysiology is still poorly defined.’.? Careful human leukocyte anti- 
gen matching is extremely important for a successful outcome. GVHD can be 
prevented through the administration of methotrexate, cyclosporine, prednisone, 
and/or tacrolimus and depletion of donor T-cells.’” The disease can be divided into 
acute (occurring within 80 days after the transplant) and chronic stages (starting after 
80 days).’.6 Chronic GVHD (c-GVHD) can be classified as progressive (evolving directly 
from the acute form), quiescent or interrupted (following a period of resolution of acute 
GVHD) or de novo (developing with no prior history of GVHD). The chronic form rep- 
resents the majority of the cases and has the best prognosis of all types.’,’ The most 
common staging system designates GVHD as limited when only localized skin involve- 
ment or hepatic dysfunction is present, or extensive when i t  involves the skin, liver, 
eyes, minor salivary glands, oral mucosa, or any other target 0rgan.l Children receiv- 
ing unrelated donor grafts have a c-GVHD incidence rate of approximately 40%; 
however, the true incidence is difficult to quantify due to the marked heterogeneity in 
GVHD prophylaxis and stem cell sources.’“ 
Increased numbers of c-GVHD sur- 
vivors are likely to be seen in dental 
practice because of higher rates of sur- 
vival due to advances in HSCT. Painful 
oral lesions may significantly impede the 
ability of persons with c-GVHD to eat, 
swallow, and carry out personal oral 
hygiene. Dental and oral care can be 
challenging for these patients. This paper 
discusses the manifestations and treat- 
ment of oral c-GVHD and reports on a 
15-month-old girl with GVHD who had 
an unusual periodontal presentation, 
which resulted in early loss of her pri- 
mary teeth. 
Case r e p o r t  
The female patient was diagnosed with 
acute non-lymphocytic leukemia, type 
MO (minimally differentiated), at the age 
of 7 months. She was treated according 
to protocol 2891 of the Children’s Cancer 
Group, initially receiving two cycles of 
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dexamethasone, cytarabine, thioguanine, 
etoposide and rubidomycin. Her medical 
history showed that she had 7q deletion, 
high initial white cell count 
(>100,00O/mm’) and failure to respond 
to the induction therapy which made her 
leukemia high risk; therefore HSCT was 
recommended. The patient had a pre- 
transplant oral screening in our dental 
clinic which revealed no abnormalities. 
The parents were advised about oral care 
and the possible acute and long-term 
effects of treatment in the craniofacial 
complex. She received a full-match, 
unrelated donor HSCT at the age of 15 
months. Her conditioning regimen con- 
sisted of busulfan, cytarabine and 
cyclophosphaniide (Cytoxan), and 
GVHD prophylaxis was done with 
tacrolimus and methotrexate. She was 
discharged on day +21 on several med- 
ications, including antibiotics, antiviral 
and antifungal agents. On day +45, she 
returned with acute GVHD in the skin 
which was controlled with oral 
tacrolimus. The day +lo0 work-up 
showed that the disease had progressed 
to chronic, involving the skin and the 
intestines. On day +236, a diagnosis of 
recurrent leukemia was made and she 
subsequently received donor lymphocyte 
infusions. On day +622, an oral examina- 
tion revealed atrophic lips, decreased oral 
opening and an ulcerated lesion on the 
dorsum of the tongue. A dexamethasone 
rinse (lmg/ml) was prescribed with 
orders to swab the oral cavity for approx- 
imately two minutes four to six times a 
day for seven days. This treatment led to 
the resolution of the lesion. One month 
later, new tongue ulcers, complete anky- 
loglossia, and gingival recession with 
exposure of the cervical third of the inci- 
sor roots were seen. Some of the incisors 
had a mobility of grade 2. Severe oral 
dryness was seen based on the patient’s 
subjective complaint of dryness and clin- 
ical assessment of mucosal dryness and 
absence of saliva pooling on the floor of 
the mouth. Because she was very sick, it 
was decided not to treat the teeth at that 
point. Cultures were difficult to obtain 
due to her age-appropriate non-compli- 
ant behavior and excessive oral dryness. 
A dexamethasone swab was used but it 
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Figure 1. Severe gingival recession of the maxillary teeth. 
was not effective, thus fluocinonide 
0.05% gel was prescribed. I t  was applied 
with a cotton tip to the affected areas 
twice daily for 10 days. Her clinical signs 
and symptoms improved significantly 
with this treatment. A small amount of 
fluoride gel on the toothbrush was pre- 
scribed to be used daily at bedtime for 
caries prevention. Four months later, the 
patient returned with complaints of oral 
pain. She now had a very limited oral 
opening due to perioral fibrosis. She also 
had facial edema, oral dryness, extensive 
lichenoid changes in the buccal mucosa, 
complete ankyloglossia, tongue ulcera- 
tions, and generalized gingival recession 
exposing the roots of most primary teeth 
(Figures 1 and 2) with increased mobil- 
ity of most incisors. An application of 2Oh 
viscous lidocaine with a cotton tip on the 
lesions was suggested for pain relief. She 
was prescribed clobetasol 0.05% gel to be 
applied to the oral mucosa twice daily 
for 10 days. A few days later, the patient 
needed a medical procedure under gen- 
eral anesthesia and while she was orally 
intubated, occlusal restorations were 
placed on teeth #B and #S and teeth #E, 
F, G, 0, and P were extracted due to 
their mobility and poor prognosis. 
Radiographs were made but were not of 
diagnostic quality due to the difficulties 
encountered in placing the films in her 
small oral cavity along with the other 
problems such as the oral intubation, 
ankyloglossia, fibrosis, etc. No soft tissue 
biopsy was taken because both the med- 
ical and dental teams agreed that the 
clinical picture was consistent with oral 
c-GVHD and that elective invasive proce- 
dures should be avoided because of her 
immunosuppression. She was given 
intravenous clindamycin for endocarditis 
prophylaxis because she had a central 
line placed and she was allergic to 
cephalosporins.’ Oral cultures grew 
gram-negative cocci and rods as well as 
coagulase-positive staphylococcus. No 
viruses were identified in the cultures. 
Later that month, she developed exten- 
sive bilateral erosive lesions on the 
buccal mucosa with severe oral pain 
which was controlled with oxycodone. A 
relapse of her leukemia was diagnosed 
and she died after a complicated hospital 
course a few days later. 
Discussion 
Chronic GVHD is the most common 
non-relapse problem affecting survivors 
of allogeneic HSCT, and is associated 
with pronounced immunosuppression.’ 
Therefore, patient/family education, pro- 
phylaxis for infection and rigorous 
medical and dental follow-up are impor- 
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Figure 2. Severe gingival recession of the mandibular teeth. 
tant measures for early diagnosis and 
management of the disease and oppor- 
tunistic infections.?,' Biopsies and other 
tests should only be done to rule out 
alternative etiologies and to confirm the 
diagnosis of GVHD.',' Systemic treatment 
for GVHD includes prednisone, 
cyclosporine, tacrolimus, azathioprine, 
thalidomide, clofazimine, psoralen plus 
ultraviolet A (PUVA), and extracorporeal 
photochemotherapy (ECP). Treatment 
needs to continue for at least six to nine 
months or until all clinical and patholog- 
ical evidence of the disease has 
disappeared.' Deaths from c-GVHD 
are usually due to infection.'.' In pedi- 
atric patients, the disease and/or its 
treatment can inhibit growth, although 
most children catch up once the disease 
is controlled and immunosuppression 
has occurred.L 
A review of the literature showed 
only a few studies of oral c-GVHD mani- 
festations in children, all of which 
stressed the need for systematic research 
of the disease in pediatric patients and 
development of adequate treatment 
strategiesq lo ' I  The oral cavity may be the 
primary or only site of c-GVHD prob- 
lems and may show persistent lesions 
after its resolution in other areas.'" 
Approximately 80% of patients with 
extensive c-GVHD present some type of 
oral problems.4 Increasing oral dryness, 
pain and/or lesions around day +lo0 can 
he an indication of the disease.' The 
most comprehensive pediatric study was 
done by Treister et al." who described the 
oral findings in 49 consecutive patients 
seen in a pediatric multidisciplinary c- 
GVHD clinic. Almost half of the children 
had a diagnosis of oral c-GVHD. The 
most common findings were reticular, 
erythematous and ulcerative lesions, 
atrophic glossitis, gross caries and soft 
tissue fibrosis, which caused limited 
opening of the mouth due to either scle- 
rosis of the facial skin or limited mobility 
of the soft tissues. Mucoceles and some 
soft tissue growths were also noted. A 
few patients complained of oral pain and 
20% avoided certain foods, particularly 
spicy and acidic products, although none 
had difficulties swallowing. There was an 
apparent lack of salivary gland involve- 
ment with only a few subjects reporting 
dry mouth (xerostomia) or objective evi- 
dence of hyposalivation. Dahllof et al.'O 
described six children with c-GVHD who 
presented with erythema of the mucous 
membranes, tongue atrophy and 
lichenoid changes in the buccal mucosa. 
Clinicians rely on oral biopsies and 
oral examinations to diagnose the disease 
and both have high predictive values of 
extensive c-GVHD.' I' Evaluation of 
biopsy of the lower labial minor salivary 
glands show ductal necrosis, sialadenitis, 
epithelial lymphocytic infiltration and 
acinar destruction.'> Oral c-GVHD 
closely resembles autoimmune connec- 
tive tissue diseases such as lichen planus 
(oral mucosa) and Sjcjgren's syndrome 
(salivary glands), with mucosal ery- 
thema, atrophy, pseudomembrane 
ulcerations, hyperkeratotic striae, includ- 
ing plaques and papules."~" Reticular 
lesions rarely require treatment whereas 
erythematous and ulcerative lesions need 
aggressive intervention." In the patient 
described in this paper, ankyloglossia 
and perioral sclerodermatous changes 
increase the difficulties with nutrition 
and oral hygiene as well as dental care. 
Patients with HSCT and c-GVHD 
may be a t  increased risk for periodontal 
disease because of immunosuppression 
and alterations in the subgingival flora. 
The most striking aspect of this case 
report was the severe, progressive, gener- 
alized gingival recession with exposure 
of the roots of primary teeth and bone 
loss, which led to premature tooth loss. 
We were unable to find any previous 
reports of pediatric GVHD that presented 
such extensive periodontal involvement. 
No systematic studies of periodontal 
health in c-GVHD have been published. 
Pattni et al." observed a slight loss of 
attachment in adult HSCT recipients but 
did not follow them long enough to 
describe any effects of GVHD on the 
periodontium. 
C-GVHD can injure salivary glands, 
leading to xerostomia and the formation 
of m~coceles."."~~' There is a direct corre- 
lation between the degree of 
hyposalivation and GVHD severity, and 
assessing salivary gland function is a 
simple, non-invasive way to monitor the 
disease.l' The saliva shows alteration in 
its biochemical and immunological com- 
position, making the patient more 
susceptible to epithelial insults and ful- 
minate infections.'" Surprisingly, rampant 
caries doesn't develop often despite the 
marked xerostomia.' Optimal oral 
hygiene is important to reduce local 
infection. Topical fluoride should be used 
for caries pre~ention.',~ A review of cur- 
rent therapies for xerostomia associated 
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with cancer therapies is described else- 
where. ’’ 
oral c-GVHD relies on successful sys- 
temic treatment but in many patients 
that may not completely resolve severe 
atrophic and ulcerative lesions.’5 
Extracorporeal photochemotherapy, for 
example, does not prevent evolution of 
the oral lesions.” In such situations, man- 
agement is focused on the treatment of 
specific lesions, pain control, relief of 
dryness and maintenance of oral health.’ 
Fluocinonide and clobetasol steroid gels 
can be used for localized lesions; dexam- 
ethasone or betamethasone rinses may he 
used for generalized involvement.’ ’ ”  As 
seen in our patient, their efficacy had 
mixed results, partly because their use is 
restricted due to difficulty retaining the 
topical medication locally and allowing 
uptake by the lesional tissue.‘,’ Rinses 
with cyclosporine, budesonide and aza- 
thioprine, tacrolimus ointment, PUVA 
therapy, and ultraviolet B irradiation have 
also been used.’”.’* z z When one or two 
large lesions are present, intralesional 
injections with triamcinolone or triamci- 
nolone acetonide may be beneficial.‘ 
Thalidomide may be considered for 
patients who don’t respond to systemic 
and/or topical steroids.’ Resistant symp- 
tomatic oral lesions may be caused by 
overgrowth or reactivation of herpes 
virus or cytomegalovirus.‘ Careful 
follow-up, with the use of appropriate 
cultures and even biopsy with immunos- 
taining for herpes group viruses, can 
ensure timely treatment of these infec- 
tions which usually have an atypical 
presentation.’ 
Topical anesthetics, systemic analge- 
sia and soothing saline rinses help 
control oral pain.‘ Anesthetic solutions, 
such as 2% viscous lidocaine, must be 
used judiciously. Patients should avoid 
gargling or swallowing local anesthetic 
solutions to keep the gag reflex intact. 
Moreover, the frequent use (more than 
once every 30 to 60 minutes) of anes- 
thetic solutions may give rise to toxic 
blood levels with complications, espe- 
cially where injured mucosal tissues are 
present.” Systemic pain medications 
should start with non-narcotics and 
The best strategy for management of 
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progress to agents containing codeine or 
hydrocodone or stronger opiates such as 
meperidine and morphine.‘ During the 
patient’s last hospitalization, intravenous 
morphine was not enough to control oral 
pain; only hydromorphone could accom- 
plish this. Throughout treatment, she 
also used oral methadone and oxycodone 
when sublingual morphine was ineffec- 
tive. 
The risk of secondary cancers is 
highest among children who undergo a 
HSCT procedure before 10 years of age.’+ 
Male gender and c-GVHD are signifi- 
cantly linked with a higher risk of 
squamous cell carcinoma of the 
Therefore, any suspicious lesions seen in 
long-term survivors of HSCT must be 
evaluated promptly. Non-gingival, benign 
soft tissue growths - possibly linked to 
cyclosporine or tacrolimus use - have 
also been reported in patients with 
GVHD.’“ 
C o n c l u s i o n  
Very little research has been done to 
assess oral c-GVHD problems in chil- 
dren. The disease’s management in young 
patients such as ours is a challenge 
because of issues of compliance and the 
fact that most medications are available 
for adult use only. With the increasing 
numbers of long-term HSCT survivors, 
dental professionals will he faced with 
treating the oral problems of this popula- 
tion. In order to ensure survival and a 
better quality of life for the child, close 
clinical and research collaboration 
between the medical and dental teams, 
together with education of general den- 
tists and specialists, is critical for early 
diagnosis and effective treatment of the 
disease. 
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